
    
      A multi-center randomized active-controlled open-label trial

        -  Patients will be randomly assigned 1:1 to receive tenofovir (300 mg/day) or tenofovir
           (300 mg/day) plus entecavir (1 mg/day) for 48 weeks.

        -  Because over 98% of Korean patients with CHB have HBV genotype C, HBV genotype will not
           determined or be regarded as a stratification factor.

        -  Patients' treatment information before randomization will be retrospectively
           collected.(DNA change, HBeAg status, HBsAg titre, ALT, and treatment duration. etc)

        -  Patients will be screened within 4 weeks before randomization to determine study
           eligibility.
    
  